Matched Treated: Short-term Disability vs Matched Untreated: Short-term Disability: Number of Participants With Any Short Term Disability (STD) Claim: Matched Participants
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0669 | 0.0636 | 0.0705 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0921 | 0.0882 | 0.0962 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0252 | -0.0305 | -0.0199 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.727 | 0.679 | 0.777 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.707 | 0.657 | 0.761 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Matched Treated: Short-term Disability than on Matched Untreated: Short-term Disability | 39.7 | 32.8 | 50.3 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Matched Treated: Short-term Disability | Participants who received NMV/r for COVID-19 and were eligible for short term disability, were included in this cohort. This arm contains participants who were matched for pre-defined characteristics and are the matched/ adjusted numbers. | 1,343 | 20,065 | OG000 | ClinicalTrials.gov |
| Group 2 | Matched Untreated: Short-term Disability | Participants who did not receive any antiviral therapy for COVID-19 and were eligible for short term disability, were included in this cohort. This arm contains participants who were matched for pre-defined characteristics and are the matched/ adjusted numbers. | 1,848 | 20,065 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants With Any Short Term Disability (STD) Claim: Matched Participants | ClinicalTrials.gov |
| Description | Number of participants with presence of any STD claim was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis. | ClinicalTrials.gov |
| Time frame | From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study | ClinicalTrials.gov |
| Population | Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated) who were eligible STD. Here, N=numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population). | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe | ClinicalTrials.gov |
| NCT number | NCT07072793 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | COVID-19 (Coronavirus Disease 2019) | ClinicalTrials.gov |
| Interventions | nirmatrelvir-ritonavir | ClinicalTrials.gov |
| Lead sponsor | Pfizer | ClinicalTrials.gov |
| Results first posted | 2026-01-12 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT07072793?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.